Lexaria's Robust Patent Portfolio Continues to Grow

  Lexaria receives 5 new patents including 2 for diabetes treatment utilizing GLP-1 drugs   Kelowna, British Columbia – March 26, 2026 – TheNewswire – Lexaria Bioscience Corp. (Nasdaq: LEXX), (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to provide this update on additional new intellectual property (“IP”) granted to the Company as a result of its ongoing research and development (“R&D”) programs. This new IP is recognized with the awarding of 5 new patents as det ...